The portfolio includes approximately 45 commercial products, four pipeline products and 40 approved non-marketed products, including a number of generic products focused on women’s health.
The agreement between Eli Lilly and Janssen was established to allow the two companies to share resources for the goal of accelerating the evaluation of the respective companies’ assets, mirikizumab and Tremfya (guselkumab).
ANSSI Wellness launches Asia’s premier and USA-patented ‘Spinal Decompression Treatment’ center in Nashik
Diclofenac epolamine topical system 1.3% offers patients a non-opioid topical treatment
Allam was serving recently as the CEO at Public Investment Fund
Ryzneuta is a novel dimeric G- CSF long-acting fusion protein without pegylation. The Biologics License Application (BLA) of Ryzneuta is currently under late-stage review by the US FDA for Chemotherapy-Induced Neutropenia (CIN)
Acetaminophen injection had annual sales of US $72 million in the United States according to IQVIA data
The company has partnered with Neethi, a Kerala state cooperative consumers federation limited company, to run this program in Kerala
Both the plants have a total Capex of Rs. 75 crore and expected production timeline is Q3 FY23
The two generic drugs have been launched under the brand names Jankey & Sitenali.
Subscribe To Our Newsletter & Stay Updated
